Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with an Overweight rating and a $606 price target, voicing confidence about Vertex’s renal franchise, implying that it might achieve significant market attention in 2026 and perhaps follow the success established by the company’s cystic fibrosis (CF) operation. The firm emphasized that Vertex’s CF therapies continue to rake in significant cash flows, which could allow for future commercial development.

Barclays expects Vertex’s IgAN (immunoglobulin A nephropathy) program to yield encouraging results early this year, adding that the renal franchise’s prospects continue to be “underappreciated” by the market.

Barclays also mentioned Journavx, claiming that the increase in prescriptions and revenues in 2026 has lately been “overlooked” by the market.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company. It develops and commercializes therapies for serious diseases, with a primary focus on cystic fibrosis and genetic disorders.

While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.